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ABSTRACT
Background Identiﬁcation of parameters for early
diagnosis and treatment response would be beneﬁcial for
patients with early rheumatoid arthritis (ERA) to prevent
ongoing joint damage. miRNAs have features of potential
biomarkers, and an altered expression of miRNAs was
shown in established rheumatoid arthritis (RA).
Objective To analyse RA associated miRNAs in the sera
of patients with ERA to ﬁnd markers of early disease,
clinical activity or predictors of disease outcome.
Methods Total RNA was isolated from whole sera in ERA
patients (prior to and after 3 and 12 months of therapy
with disease modifying antirheumatic drugs), in patients
with established RA and in healthy controls (HC) using
phenol–chloroform extraction. Expression of miR-146a,
miR-155, miR-223, miR-16, miR-203, miR-132 and
miR-124a was analysed by TaqMan Real Time PCR.
Results From all analysed miRNAs, levels of miR-146a,
miR-155 and miR-16 were decreased in the sera of ERA
patients in comparison with established RA. A change
in circulating miR-16 in the ﬁrst 3 months of therapy was
associated with a decrease in DAS28 in long term follow-
up in ERA (p=0.002). Levels of circulating miR-223 in
treatment naïve ERA correlated with C reactive protein
(p=0.008), DAS28 (p=0.031) and change in DAS28 after
3 months (p=0.003) and 12 months (p=0.011) of follow-
up. However, neither miR-16 nor miR-223 could
distinguish ERA from HC.
Conclusions Differential expression of circulating miR-
146a, miR-155 and miR-16 in the sera of ERA patients
may characterise an early stage of the disease. We suggest
miR-223 as a marker of disease activity and miR-16 and
miR-223 as possible predictors for disease outcome in
ERA.
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic, inﬂamma-
tory, autoimmune disorder with progressive articu-
lar damage that may result in severe lifelong
disability. A considerable number of RA patients
develop severe disability early in the disease.1
Studies have shown a beneﬁcial effect of early treat-
ment on clinical outcome and reduction in joint
damage that prevents irreversible joint destruction
and disability.2–4 In addition, a delay of a few
months from the onset of symptoms to the institu-
tion of therapy decreases the ability of the
traditional single drug strategy to induce remission
in early rheumatoid arthritis (ERA).5–7 Therefore,
in order to deﬁne patients at earlier stages of the
disease who would beneﬁt from early effective
intervention, new RA classiﬁcation criteria were
developed.8 However, while some patients proﬁt
from initial monotherapy, others fail to demon-
strate clinical or radiological responses, even to
combination therapy.9 Until now, several predictors
of response to disease modifying antirheumatic
drugs (DMARD) and biological treatments such as
cytokine proﬁles or gene expression analysis have
been described but are either impractical or lack
speciﬁcity to be adopted in daily clinical prac-
tice.9 10 Therefore, it is important to ﬁnd para-
meters that identify patients with early arthritis and
to ﬁnd predictors of treatment response in ERA to
optimise individual management of early arthritis
based on the expected disease course and to
prevent over or under treatment.8–10
miRNAs are short single stranded non-coding
RNAs involved in the post-transcriptional regulation
of gene expression.11 Altered expression of miRNAs
has been described under various pathological con-
ditions, including rheumatic and other autoimmune
diseases.12 13 We and others reported that
miR-146a, miR-155 and miR-203 are overexpressed
while miR-124a appeared suppressed in RA synovial
ﬁbroblasts.14–17 Dysregulation of miR-146a,
miR-155, miR-223, miR-16 and miR-132 was
observed in immune cells derived from patients with
RA.14 18–22 As miRNAs are stably present in cell free
form in body ﬂuids and circulating miRNAs were
shown to have signatures related to tumour classiﬁ-
cation and disease progression, they are becoming
new candidate biomarkers for diagnosis and prog-
nosis in different diseases.23–25 Although expression
of several miRNAs has recently been analysed in
plasma and synovial ﬂuid of patients with estab-
lished RA and osteoarthritis,26 there are no reports
to date on the important phase of ERA.
The aim of our study was to analyse the proﬁle
of selected RA related cell free circulating miRNAs
in the sera of patients with ERA prior to and after
therapy with DMARD, in established RA and in
healthy controls (HC). Using this approach, we
hoped to identify potential tools distinguishing
early and late phases of the disease, markers of
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clinical activity or predictors of disease outcome. In addition,
we analysed intracellular expression of these miRNAs in syn-
ovial ﬁbroblasts from patients with ERA.
MATERIAL AND METHODS
Collection of sera and characteristics of patients with RA
Sera and clinical details from 34 patients with ERA who fulﬁlled
the 2010 American College of Rheumatology (ACR)/European
League Against Rheumatism (EULAR) classiﬁcation criteria for
RA8 with a symptom duration <8 months were obtained at
baseline, and at 3 and 12 months after treatment. Patients with
ERA were recruited from the outpatient clinic of the Institute of
Rheumatology, Prague. Sera from 28 patients with established
treated RA of disease duration 9.28±6.52 years who fulﬁlled
the 1987 revised ACR criteria for the classiﬁcation of RA27 were
obtained from both the Department of Rheumatology,
University Hospital, Zurich, and the Institute of Rheumatology,
Prague. Clinical characteristics of the patients and the 16 HC
(University Hospital, Zurich) are shown in table 1. Written
informed consent was obtained from all participants, and the
study was approved by the local ethics committees.
Synovial ﬁbroblasts from patients with inﬂammatory
arthritis
Synovial ﬁbroblasts (SF) were isolated from synovial tissues
obtained during ultrasound guided synovial tissue biopsy
(University of Birmingham, UK). Synovial tissue samples were
taken from patients with untreated ERA (n=7) with a disease dur-
ation <13 months who met the 1987 ACR criteria,27 from
patients with knee pain of non-inﬂammatory origin (n=9) and
from patients with resolving arthritis different from RA (n=14).
Written informed consent was obtained from each donor, and the
study was approved by the local ethics committee. For a detailed
description of the methods, see online supplementary material.
Expression of miRNAs was analysed by TaqMan Real Time
PCR. The dCt method was used for relative quantiﬁcation of
miRNA. dCt was calculated as follows: Ct (let−7a) − Ct (miRNA
of interest) and therefore higher dCt values represent higher
expression. The data summarising the establishment of the
method for the detection of miRNAs in sera are given in the
online supplementary material (see online supplementary
ﬁgure 1).
RESULTS
Circulating miRNAs are differentially expressed in the sera
of patients with ERA and established RA
As several miRNAs have been reported to show altered expres-
sion in immune cells, SF, plasma or synovial ﬂuid from patients
with established RA, we anticipated dysregulation of circulating
miRNAs at the onset of the disease in comparison with the estab-
lished state. Considering circulating miRNAs as potential biomar-
kers, their analysis in sera would be of interest due to easy
accessibility of samples for clinical use. Therefore, analysis of RA
related miR-146a, miR-155, miR-203, miR-124a, miR-223,
miR-16 and miR-132 in sera was performed in patients with
treatment naïve ERA, established treated RA and HC.
Levels of miR-146a were signiﬁcantly lower in the sera of
patients with ERA (dCt 0.44±0.93) in comparison with patients
with established RA (dCt 1.20±1.00, p<0.01) or HC (dCt
1.27±1.07, p<0.05). There was no difference between estab-
lished RA and HC (ﬁgure 1A). Circulating miR-155 in ERA
patients (dCt −6.31±1.05) showed comparable levels with HC
(dCt −5.84±1.24) while it signiﬁcantly differed from patients
with established RA who demonstrated higher levels of miR-155
(dCt −4.68±1.86, p<0.001) (ﬁgure 1B). Similarly, miR-16 was
Table 1 Characteristics of patients with early and established rheumatoid arthritis, and healthy controls, whose sera were used for analysis of
expression of circulating miRNAs in the present study
Early RA Established RA Healthy controls
Sex (F/M) 25/9 17/9 9/7
Age (years) 47.30±14.41 57.89±13.29 39.00±14.12
Disease duration <8 months 9.28±6.52 years 0
Treatment Baseline 3 months 12 months
Methotrexate 0 28 28 14 0
Sulfasalazine 0 4 4 2 0
Leflunomide 0 1 1 8 0
Glucocorticoids 0 30 30 6 0
Biologics 0 0 0 19 0
Clinical characteristics Baseline 3 months 12 months
n 31 31 32 28 16
RF positivity (%) 64.52 NA 66.67 85.71 NA
IgG RF (U/mL) 31.79±42.86 NA 19.83±17.48 NA NA
IgM RF (U/mL) 78.01±225.50 NA 84.89±186.30 NA NA
IgA RF (U/mL) 59.14±102.70 NA 36.54±79.37 NA NA
ACPA positivity (%) 51.61 NA 48.48 85.71 NA
ACPA (mmol/L) 1018±1871 NA 973±1600 NA
DAS28 5.41±1.61 2.60±1.21*** 2.54±1.18*** 4.10±1.32 NA
CRP (mg/L) 18.36±23.30 4.03±6.60*** 2.77±2.57*** 21.05±37.58 NA
ESR (mm/h) 31.00±19.52 15.09±9.87*** 11.43±7.71*** NA NA
Leucocytes ×109/mm3 8.34±2.53 7.41±1.74 6.70±2.72** NA NA
Data are expressed as the mean±SD.
*p<0.05, **p<0.01, ***p<0.001 compared with baseline.
ACPA, anticitrullinated proteins antibodies; CRP, C reactive protein; DAS28, disease activity score calculated with ESR; ESR, erythrocyte sedimentation rate; NA, not analysed; RA,
rheumatoid arthritis; RF, rheumatoid factor.
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found at signiﬁcantly lower levels in the sera of patients with
ERA (dCt 4.93±0.91) than in patients with established RA (dCt
6.10±1.22, p<0.001) while it was comparable with HC (dCt
5.23±1.25). The levels of miR-16 in established RA were higher
than in HC but did not reach statistical signiﬁcance (ﬁgure 1C).
The patterns of miR-132 and miR-223 were not different in
ERA, established RA and HC (dCt −4.31±0.90, −3.76±1.07,
−4.41±1.23 for miR-132; dCt 5.67±1.04, 6.23±1.45, 5.55
±0.77 for miR-223). MiR-124a and miR-203 in sera were
present in negligible amounts close to the detection limit and
were therefore excluded from further analysis (data not shown).
Change in circulating miR-16 during therapy is associated
with decreasing disease activity
Subsequently, the effect of therapy with DMARDs on levels of
miRNAs was explored in ERA patients. Also, the association of
circulating miRNAs with markers of disease activity in ERA and
established RA was evaluated. Follow-up within 3 months (M3)
after initiation of therapy appeared to be a very important time
point with respect to clinical response and prediction of
outcome at 12 months (M12).28 29
Levels of miR-16 increased by 34.31% in 24/34 ERA patients
after 3 months of therapy. Although miR-16 was the only
miRNA analysed in our study, showing a trend towards higher
levels after 3 months of treatment with DMARDs (dCt
4.93±0.91 vs 5.71±1.27), it did not reach statistical signiﬁcance
in the whole group of ERA patients. However, levels of miR-16
at M12 (dCt 3.85±1.37) signiﬁcantly decreased in comparison
with both baseline (p<0.05) and M3 (p<0.001, ﬁgure 2A). In
addition, the increase in miR-16 at M3 was veriﬁed by an inde-
pendent method using TaqMan Low Density Arrays cards
(TLDAs) (3.768-fold change, see online supplementary table 1).
The effect of different treatment modalities on levels of miR-16
is given in the online supplementary table 2.
Higher levels of miR-16 at baseline correlated with a greater
improvement in disease activity, represented by a larger decrease
in DAS28 from baseline to M3 (r=−0.478, p=0.008) (ﬁgure
2B). Similarly, levels of miR-16 at M3 correlated with a change
in disease activity ΔDAS28 from M3 to M12 (r=−0.355,
p=0.047) (ﬁgure 2C). Most importantly, the change in levels of
miR-16 from baseline to M3 were negatively associated with the
change in DAS28 from M3 to M12 (r=−0.519, p=0.002)
(ﬁgure 2D) suggesting that the increase in circulating miR-16
within the ﬁrst 3 months after treatment initiation was followed
by the decrease in disease activity in the subsequent 9 months.
Interestingly, levels of miR-16 at baseline negatively correlated
with levels of anticitrullinated protein antibodies (ACPA) (r=
−0.365, p=0.037). However, levels of miR-16 did not correlate
with C reactive protein (CRP), erythrocyte sedimentation rate
or IgG, IgM or IgA rheumatoid factors (RF) at baseline, M3 or
M12 (data not shown).
Although differentially expressed in ERA sera in comparison
with established RA sera, levels of circulating miR-16 showed
no association with disease activity in established RA (data not
shown).
MiR-223 as a marker of disease activity in treatment naïve
ERA and its association with disease outcome during short
and long time follow-up
Levels of miR-223 were found to be decreased by 17.65% in
24/34 ERA patients 3 months after treatment initiation.
However, in the group of all ERA patients, the change in levels
of miR-223 at M3 in comparison with baseline did not reach
statistical signiﬁcance (dCt 5.67±0.104 vs 5.12±0.91). In fact,
after 12 months of treatment, levels of miR-223 (dCt
4.34±0.78) signiﬁcantly decreased in comparison with levels at
baseline (p<0.001) and at M3 (p<0.01) (ﬁgure 3A). Further
analysis using TLDA cards showed no change in miR-223 at M3
(1.065-fold change) but conﬁrmed the decreased levels of
miR-223 at M12 (0.692-fold change, see online supplementary
table 1). The effect of different treatment modalities on levels of
miR-223 is given in the online supplementary table 2.
In ERA prior to treatment initiation, levels of miR-223 posi-
tively correlated with CRP (r=0.519, p=0.008 ﬁgure 3B) and
with DAS28 (r=0.389, p=0.031) (ﬁgure 3C) at baseline.
Importantly, levels of miR-223 at baseline correlated with the
decrease in DAS28 from baseline to M3 (r=−0.522, p=0.003)
(ﬁgure 3D) as well as from baseline to M12 (r=−0.460,
p=0.011) (ﬁgure 3E). Moreover, the greater decrease in levels
of miR-223 from baseline to M12, the more improvement in
Figure 1 Comparison of levels of circulating miR-146a (A), miR-155
(B) and miR-16 (C) in the sera of patients with treatment naïve early
rheumatoid arthritis (ERA), established rheumatoid arthritis (RA) and
healthy controls (HC). *p<0.05, **p<0.01, ***p<0.001. dCt was
calculated as follows: Ct (let−7a) − Ct (miRNA of interest) and
therefore higher dCt values represent higher levels. Broken line refers
to levels of miRNAs in established RA.
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DAS28 was observed after 12 months of therapy (r=0.483,
p=0.006) (ﬁgure 3F). In contrast with signiﬁcant correlations of
miR-223 with disease activity in ERA patients before treatment,
levels of miR-223 did not correlate with parameters of disease
activity (DAS28 or CRP), or levels of ACPA, IgG, IgM or IgA
RF at M3 or M12 after initiation of therapy (data not shown).
In established RA, levels of miR-223 showed no correlation
with disease activity (data not shown).
In addition, neither miR-146a nor miR-155 or miR-132
showed any association with disease activity in patients with
ERA at baseline, M3 or M12, or in patients with established RA
or any change in expression after therapy in ERA (data not
shown).
Decrease in levels of miR-223 in sera follows change
in peripheral leucocyte count
We found a signiﬁcant correlation between baseline levels of
miR-223 and peripheral leucocyte (PL) count in patients with
ERA (r=0.459, p=0.007) (ﬁgure 4A). Therefore, we were inter-
ested in whether the change in levels of miR-223 after treatment
followed the change in PL count. In fact, the larger decrease in
miR-223 between baseline and M3 positively correlated with
the decrease in PL count between these two time points
(r=0.397, p=0.025) (ﬁgure 4B). Also, the changes in levels of
miR-223 and PL count within the whole period of 12 months
correlated signiﬁcantly (r=0.621, p=0.0001) (ﬁgure 4C). This
suggests that the decrease in miR-223 in the sera of ERA
patients after therapy is very likely attributable to the change in
the number of PLs.
Expression of miRNAs in synovial ﬁbroblasts from patients
with ERA
Based on different levels of miRNAs in ERA reported here, we
anticipated dysregulation of miRNAs in SF from patients with
ERA. Therefore, expression of miR-146a, miR-155, miR-203,
miR-124a, miR-223, miR-16 and miR-132 was analysed in iso-
lated SF cultured in vitro.
In contrast with differences in levels of miRNAs observed in
sera, there were no signiﬁcant differences in expression of
miRNAs analysed in our study among SF from patients with
ERA, resolving arthritis of different disease entities as an
example of non-RA arthritis and controls with non-
inﬂammatory arthralgia (see online supplementary ﬁgure 2)
DISCUSSION
RA is a chronic inﬂammatory disease characterised by progres-
sive joint destruction. We and others have shown that altered
expression of miRNAs in immune and resident cells involved in
the pathogenesis of RA contributes to maintenance of pathog-
nomic features typical of RA.13 For example, miR-155 and
miR-146a are induced in response to inﬂammatory stimuli and
are overexpressed in RA SF in comparison with osteoarthritis
SF.14 18 30 MiR-155 acts as a positive regulator and miR-146a as
a negative regulator of inﬂammation in RA, as shown in
vivo.18 31 32 MiR-223 was shown to be overexpressed in syn-
ovial tissue of RA patients and, importantly, silencing of
miR-223 reduced disease severity in experimental arthritis.33
The evidence of high stability of miRNAs in body ﬂuids due to
incorporation into microvesicles or stabilisation in complexes
with RNA binding proteins (Argonaute 2, high density lipopro-
teins, nucleophosmin 1) and their easy accessibility make miRNA
Figure 2 Change in levels of circulating miR-16 in the sera of patients with early rheumatoid arthritis (ERA) from baseline (M0) to 3 (M3) and
12 (M12) months after treatment with disease modifying antirheumatic drugs (A). *p<0.05, ***p<0.001. Levels of miR-16 (dCt) at baseline (M0)
correlated with change in DAS28 (ΔDAS28) from M0 to M3 (B). Levels of miR-16 in ERA sera at M3 correlated with ΔDAS28 from M3 to M12 (C).
Importantly, the change in levels of miR-16 (Δ dCt) from M0 to M3 was negatively associated with ΔDAS28 from M3 to M12 (D). dCt was
calculated as follows: Ct (let−7a) − Ct (miR-16) and therefore higher dCt values represent higher levels. The increase/decrease in ΔDAS28 is
indicated by a broken/full arrow, respectively.
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ideal biomarkers.23 24 34–36 Moreover, changes in the number of
miRNAs originating from blood cells or tissues and their speciﬁc
proﬁles inﬂuenced by pathophysiological conditions, such as
sepsis, have been described previously.37 Based on these data, we
anticipated that levels of circulating miRNAs in sera would be
different in patients with ERA and established RA.
We report here for the ﬁrst time reduced levels of miR-146a,
miR-155 and miR-16 in the sera of patients with ERA in compari-
son with patients with established RA. Levels of these miRNAs
were comparable between patients with established RA and HC,
similar to the data published by Murata et al,26 except for
miR-132 that was shown to be lower in RA than in HC.26
Although intracellular expression of miR-146a and miR-155 was
shown to be induced by the proinﬂammatory milieu in vitro,14 18
it is possible that cell free circulating miRNAs in sera do not neces-
sarily reﬂect levels in the intracellular compartment. In fact, release
of miRNAs may be selective due to the existence of a cellular selec-
tion mechanism for miRNA release and therefore the extracellular
and cellular miRNA proﬁles may differ.38 Secretory cell free
miRNAs were shown to transfer inhibitory signals to recipient
cells.39 Although the functional role and impact of circulating
miRNAs in living organisms remains currently unknown, we
speculate that in ERA, miR-146a and miR-155 may be extensively
taken up by recipient cells where they exert their regulatory activ-
ity. We propose that low levels of miR-146a, miR-155 and miR-16
in ERA may represent the early phase of RA. We hypothesise that
progression of disease severity, disease duration, effect of treat-
ment or other yet unknown factors can modulate levels of circulat-
ing miRNAs in established RA.
MiR-16 was reported to be overexpressed in peripheral blood
mononuclear cells of RA patients with active disease in comparison
with RA patients with low disease activity or with HC.20 We
showed here that the higher levels of miR-16 in the sera of treat-
ment naïve patients with ERA correlated with better improvement
in disease activity during the 3 months of follow-up. This is
important because most clinical responses in ERA are seen in the
ﬁrst 3 months of therapy, as shown in table 1. In addition, change
in levels of circulating miR-16 within the ﬁrst 3 months after initi-
ation of therapy is associated with disease outcome in the follow-
ing 9 months.
Figure 3 Change in levels of circulating miR-223 in the sera of patients with early rheumatoid arthritis (ERA) from baseline (M0) to 3 (M3) and
12 (M12) months after treatment with disease modifying antirheumatic drugs (A). **p<0.01, ***p<0.001. Levels of circulating miR-223 (dCt) at
baseline (M0) in the sera of ERA patients correlated with the levels of C reactive protein (CRP) (B) and disease activity (DAS28) (C) at M0. Levels of
circulating miR-223 at M0 correlated with the change in DAS28 (ΔDAS28) from M0 to M3 (D) as well as M12 (E). Change in levels of miR-223 from
M0 to M12 correlated with ΔDAS28 from M0 to M12 (F). dCt was calculated as follows: Ct (let−7a) − Ct (miR-223) and therefore higher dCt
values represent higher levels. The decrease in ΔDAS28 is indicated by a full arrow.
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MiR-223 was recently demonstrated to be upregulated in per-
ipheral T cells from patients with early as well as established RA
compared with HC, but no correlation of miR-223 in these
cells with DAS28, CRP, RF or ACPA was found in these
patients.22 40 In addition, no differences in expression of
miR-223 in T cells were observed in untreated RA patients and
those treated with glucocorticoids.22 Although not differentially
expressed in the sera of ERA and RA patients, we suggest circu-
lating cell free miR-223 as a marker of disease activity in treat-
ment naïve patients with ERA based on signiﬁcant associations
with CRP and DAS28. At the same time, higher baseline levels
of circulating miR-223 were associated with better improvement
in disease activity in ERA after the therapeutic intervention. We
suggest that levels of miR-16 and miR-223 may characterise
patients with good/worse response to therapy.
In the study, we showed the changes in levels of miR-16 and
miR-223 over time after initiation of therapy. We suggest that
the decrease in miR-223 in ERA sera after therapy may be
attributed to change in PL count. Accordingly, haematopoietic
cells express miR-223 and are considered an important source
of circulating miR-223.37 41 Although the main source of circu-
lating miRNAs is currently unknown, they can originate from
heterogenous cells, such as circulating blood cells or cells in
organs. Therefore, we speculate that differential levels of
miR-16 and miR-223 in the sera of ERA patients after therapy
may reﬂect altered expression in blood cells or solid tissues.13
Apart from the contribution of inﬂammatory cells abundantly
present in the hyperplastic RA synovium, SF are believed to
actively drive joint inﬂammation and destruction.42 43 Although
we observed different levels of miRNAs in ERA sera, we did not
see any differences in SF from patients with ERA cultivated in
vitro, possibly due to type II statistical error. As shown previ-
ously,26 ﬁbroblast-like synoviocytes, mononuclear cells and syn-
ovial tissues secrete miRNAs in distinct patterns. A differential
proﬁle of cytokines inﬂuencing the microenvironment required
for persistent RA has been observed in the synovial ﬂuids of
patients with early synovitis which developed later into RA.44
Also, distinct expression of miRNAs in synovial tissues in estab-
lished RA, as a result of chronic exposure of SF to the inﬂamma-
tory milieu accompanying RA, has been reported.14 18 33
Therefore, our data obtained in vitro in isolated SF do not
necessarily reﬂect the situation in synovial tissue. The associ-
ation of miRNAs with speciﬁc immunohistochemical ﬁndings in
synovial tissues at the early phase and how cell free miRNAs
originating from a joint compartment contribute to the spec-
trum and levels of circulating miRNAs in blood serum/plasma
remain to be investigated.
In conclusion, we have shown here for the ﬁrst time low
expression of miR-146, miR-155 and miR-16 in the sera of
patients with early in comparison with established RA. Although
further studies in larger patient cohorts are needed, our data
support circulating miR-223 as a marker of disease activity in
patients with treatment naïve ERA. Moreover, monitoring levels
of miR-16 and miR-223 may become a useful tool to predict
disease outcome in patients with ERA.
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